References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321–333
- The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen on postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291: 1701–1712
- Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
- Chevallier T, Daures J P, Micheletti M C, Reginster J Y, Groupe MISSION. Méthodologie de l'enquête MISSION (Ménopause, rISque de cancer du SeIn, mOrbidité et prévaleNce). J Gynecol Obstet Biol Reprod 2005; 34: 658–665
- Fournier A, Berrino F, Riboli E, Avenal V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114: 448–454
- de Lignières B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le M G, Kuttenn F. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002; 5: 332–340